Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Drug giant shows its commitment to stem cells

On 14 November, pharmaceutical company Pfizer announced the formation of its new stem-cell research unit, Pfizer Regenerative Medicine, which will be based in two locations on either side of the Atlantic. The site in Cambridge, UK, will focus on neural disorders, whereas the base in Cambridge, Massachusetts, will explore applications of stem-cell technology to endocrine and cardiac research.

The centres will employ about 70 scientists in total, and Pfizer plans to announce additional collaborations with academia and industry in coming weeks.

Pfizer already has a long-term interest in cell-based therapeutics, but its expanded commitment to stem-cell research is indicative of a recent investment trend by other large pharmaceutical companies eager to use stem cells for drug screening, including GlaxoSmithKline, based near London, and the Swiss companies Roche and Novartis.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Drug giant shows its commitment to stem cells. Nature 456, 293 (2008). https://doi.org/10.1038/456293c

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/456293c

Search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing